. 2020 Aug 10;31(6):e83. doi: 10.3802/jgo.2020.31.e83

Table 4. Reclassification frequency of BRCA1 and BRCA2 VUS.

Study	Type of cancer	Total No. of patients	No. of initial VUS type	No. of reviewed VUS type	Reclassified class					Reclassification method	Country
Study	Type of cancer	Total No. of patients	No. of initial VUS type	No. of reviewed VUS type	B (%)	LB (%)	VUS (%)	LP (%)	P (%)	Reclassification method	Country
Mighton et al. [21]	Breast, colon	6,090	453	154	26.6	14.9	56.5	1.3	0.6	Nationwide database	Canada
So et al. [10]	Breast, ovary	423	48	48	6.3	20.8	68.8	4.2	0.0	ACMG/AMP 2015 guideline	Korea
Lee et al. [11]	Breast	2,115	286	83	0.0	67.4	27.7	3.5	1.2	Multifactorial probability-based model	Korea
Lee et al. [11]	Breast	2,115	286	83	0.0	67.4	27.7	3.5	1.2	ACMG/AMP 2015 guideline	Korea
Park et al. [7]	HBOC	745	86	86	10.4	41.9	40.7	1.7	5.8	ACMG/AMP 2015 guideline	Korea
Present study	EOC, FTC, PPC	805	108	108	15.7	12.0	66.7	4.6	1.0	ACMG/AMP 2015 guideline	Korea

ACMG/AMP, American College of Medical Genetics and Genomics and the Association for Molecular Pathology; B, benign; EOC, epithelial ovarian cancer; FTC, fallopian tube cancer; HBOC, hereditary breast and ovarian cancer syndrome; LB, likely benign; LP, likely pathogenic; P, pathogenic; PPC, primary peritoneal cancer; VUS, variants of unknown significance.